These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32395707)

  • 1. Aptamer-functionalized Hybrid Nanoparticles to Enhance the Delivery of Doxorubicin into Breast Cancer Cells by Silencing P-glycoprotein.
    Chandra S; Michael Nguyen H; Wiltz K; Hall N; Chaudhry S; Olverson G; Mandal T; Dash S; Kundu A
    J Cancer Treatment Diagn; 2020; 4(1):1-13. PubMed ID: 32395707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
    Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
    Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes.
    Song X; Ren Y; Zhang J; Wang G; Han X; Zheng W; Zhen L
    Oncol Rep; 2015 Oct; 34(4):1953-60. PubMed ID: 26238192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
    Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
    J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA.
    Yuan Y; Liu J; Yu X; Liu X; Cheng Y; Zhou C; Li M; Shi L; Deng Y; Liu H; Wang G; Wang L; Wang Z
    Acta Biomater; 2021 Nov; 135():556-566. PubMed ID: 34496281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.
    Chowdhury N; Chaudhry S; Hall N; Olverson G; Zhang QJ; Mandal T; Dash S; Kundu A
    AAPS PharmSciTech; 2020 Jul; 21(6):202. PubMed ID: 32696338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary: "Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer".
    Evans R
    J Cancer Treatment Diagn; 2017; 1(2):16-17. PubMed ID: 31032482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
    Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
    Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
    Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
    Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
    ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer.
    Li X; Wu X; Yang H; Li L; Ye Z; Rao Y
    Biomed Pharmacother; 2019 Sep; 117():109072. PubMed ID: 31202169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
    Tiash S; Chowdhury EH
    J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
    Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
    Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming Drug Resistance in Colon Cancer by Aptamer-Mediated Targeted Co-Delivery of Drug and siRNA Using Grapefruit-Derived Nanovectors.
    Yan W; Tao M; Jiang B; Yao M; Jun Y; Dai W; Tang Z; Gao Y; Zhang L; Chen X; Wang QL
    Cell Physiol Biochem; 2018; 50(1):79-91. PubMed ID: 30278432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors.
    Xu L; Li H; Wang Y; Dong F; Wang H; Zhang S
    Oncol Lett; 2014 Feb; 7(2):387-392. PubMed ID: 24396453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
    Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
    Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.